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The International Pachyonychia 
Con genita Consortium (IPCC) is a 
group of physicians and scientists 
who have agreed to work together 
to develop therapeutics for the rare 
skin disorder pachyonychia congenita 
(PC). Each IPCC meeting is devoted 
to the most pressing issues related 
to developing PC therapeutics and 
to reach consensus on directions 
to achieve realistic goals. A list of 
IPCC members can be found on the 
organization’s website (http://www.
pachyonychia.org), and details of the 
oral presentations at this year’s annual 
meeting are listed in Supplementary 
table 1 online.
In this issue of the journal, several 
PC articles are based on presentations 
from the 2010 meeting*; they highlight 
progress and, importantly, explain how 
this new knowledge may lead to novel 
approaches in therapy. Each article is 
identified by the PC Project/IPCC ban-
ner. The consortium recognizes and 
expects that success will benefit not 
only PC patients but also individuals 
with other genetic skin disorders. The 
2010 IPCC conference was divided 
into three areas: (i) identifying and 
organizing the mutations that cause 
PC and its resulting phenotypes, (ii) 
preclinical work and clinical studies 
related to treatment or analysis of the 
effectiveness of treatment regimens, 
and (iii) progress on the delivery of 
therapeutic agents, including small 
interfering RNA (siRNA).
genetic analysis in pC
Frances Smith (University of Dundee, 
Scotland) reviewed the known genes 
and mutations that cause PC (see 
Wilson et al., 2011, this issue). PC is 
caused by dominant-negative muta-
tions in any one of the genes encod-
ing keratins K6a, K6b, K16, or K17 
(i.e., the KRT6A, KRT6B, KRT16, 
and KRT17 genes, respectively). 
Smith heads an international muta-
tion analysis service for PC (e-mail 
f.j.d.smith@dundee.ac.uk for more 
information). In particular, her group 
analyzes patients registered in the 
International Pachyonychia Congenita 
Research Registry (IPCRR). Currently, 
64 distinct mutations have been 
found in 199 IPCRR families, the larg-
est group of patients studied to date. It 
was noted at the meeting that, despite 
several isolated case reports (all of 
which lack genetic analysis), recessive 
inheritance has not been identified. 
Mutations were recently identified 
in the KRT6C gene in patients with 
painful focal plantar keratoderma, 
but with minimal or no nail changes. 
It was suggested that this gene should 
be added to the screening list for PC, 
especially in cases where nail involve-
ment is minimal. Similarly, connex-
in-30 mutations have been found in 
PC-like cases presenting with alope-
cia. Interestingly, several cases have 
emerged for which the clinical phe-
notype is indistinguishable from PC 
but in which no mutations have been 
found, suggesting that additional 
genes remain to be identified. In some 
of these cases, genetic linkage analy-
sis suggests involvement of additional 
keratin-related genes.
mining the ipCrr database
Pachyonychia Congenita Project, a 
nonprofit patient advocacy group 
(h t tp : / /www.pachyonychia .org ) , 
maintains an active patient registry, 
the IPCRR, in which participants are 
genotyped, complete an in-depth 
questionnaire, and consult with a der-
matologist expert in PC as part of the 
registration process. As the number 
of patients in the registry has grown, 
it has become increasingly clear that 
many earlier PC public ations contain 
incomplete data and/or may have 
drawn incorrect conclusions. David 
Hansen (University of Utah, Salt Lake 
City) provided an up-to-date look 
at the clinical data compiled from 
the database and identified clinical 
findings that had been incorrectly 
associated with PC in the literature, 
including mental retardation, alo-
pecia, hair deformities, and corneal 
abnormalities (Eliason et al., unpub-
lished). Furthermore, he demonstrat-
ed that the classic separation of PC 
into two subtypes of PC-1 (Jadassohn–
Lewandowski syndrome) and PC-2 
(Jackson–Lawler syndrome) is not 
justified based on genotyping and 
phenotyping of nearly 1,000 patients 
now available through the IPCRR. 
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It was proposed that this nomencla-
ture be replaced with a class ification 
system that includes the mutated gene 
when known (i.e., PC-6a, PC-6b, 
PC-16, and PC-17) or PC-U in a case 
where PC is suspected but no muta-
tion has been identified (see McLean 
et al., 2011, this issue).
A consensus emerged during the 
initial discussion period (“Organizing 
for Success,” led by Mary Schwartz, 
Director of PC Project, Salt Lake City, 
UT) that the conclusions from the 
study presented by Hansen should be 
disseminated through a variety of ven-
ues in ways that would reach those 
who diagnose PC patients, including 
dermatology, genetics, pediatrics, 
and podiatry journals. In addition, 
it would be appropriate to weed out 
incorrect information on the Internet 
by periodically monitoring com-
monly used sites such as Wikipedia. 
Furthermore, a consensus emerged 
on the need to break the cycle of cit-
ing older literature known to con-
tain errors, which could be achieved 
by encouraging rigorous review of 
new submissions. Attendees felt that 
publication of case reports without 
genotypic analysis should be strongly 
discouraged by academic journals 
because this practice increases the 
likelihood that erroneous information 
will be introduced into the literature. 
It was noted that the Pachyonychia 
Congenita Project currently covers the 
cost of genetic analysis for patients 
who are enrolled in the registry.
Now that larger sets of genotyped 
patients linked to comprehensive 
clinical data are available through the 
IPCRR, it is possible to attempt geno-
type–phenotype correlation in a statis-
tically meaningful manner. Jean Tang 
and Teresa Fu (Stanford University, Palo 
Alto, CA) presented just such a study, 
comparing groups of K16 patients har-
boring either p.Asn125 or p.Arg127 
mutations (see Fu et al., 2011, this 
issue). Of particular interest were their 
findings of variable expression patterns 
among family members with the same 
mutation, suggesting the presence of 
environmental factors and/or modifier 
genes. These developments also rep-
resent a good model in the analyses of 
other genetic disorders.
preclinical and clinical studies
An exciting aspect of the 2010 meet-
ing was the number of presentations 
on new therapeutic strategies. This 
included advances with the potential 
to be applied to PC as well as data on 
therapeutics already in use. Johann 
Bauer (Paracelsus Medical University, 
Salzburg, Austria), Dennis Roop 
(University of Colorado at Denver, 
Aurora), and Hector Zambrano-
Manrique and Leonard Milstone (Yale 
School of Medicine, New Haven, CT) 
focused on scientific breakthroughs 
that might be applicable to PC. Bauer 
reported recent success in reduc-
ing expression of mutant plectin by 
spliceosome-mediated RNA trans-
splicing (SMaRT), a method that may 
prove to be useful for the treatment of 
auto somal dominant disorders. Roop 
reviewed the recent advances in stem 
cell biology—in particular, induced 
pluripotent stem (iPS) cell produc-
tion—and the potential that this tech-
nology may move the field of regen-
erative medicine forward. He outlined 
a vision of how patient-derived skin 
cells containing an autosomal domi-
nant mutation could be harvested, 
used to produce iPS cells, corrected 
in vitro by homologous recombina-
tion, and used in an autologous trans-
plantation procedure to correct a 
gene defect. Zambrano-Manrique and 
Milstone presented their work to cor-
rect KRT6A mutations through the use 
of small donor oligonucleotides and 
triplex-forming oligonucleotides. They 
demonstrated that correction can be 
accomplished, and they are in the pro-
cess of enhancing the correction fre-
quency. Birgit Lane (A*STAR Institute 
for Molecular Biology, Singapore) 
presented the case for alternative 
approaches to therapy for keratin dis-
orders based on the basic biology of 
these proteins, for example, using type 
III intermediate filament proteins such 
as desmin to supplement the defective 
keratin cytoskeleton.
Robert Gruber and Matthias Schmuth 
(Innsbruck Medical University, Austria) 
utilized IPCRR data to identify PC 
patients who had received systemic 
retinoid treatment. Their preliminary 
analysis suggests that the ratio among 
effectiveness, pain, and adverse 
effects is more favorable with lower 
doses (Gruber et al., in press). Phillip 
Holler and Adam Rubin (Hospital 
of the University of Pennsylvania, 
Philadelphia) used IPCRR data to 
perform the first multifamily genotype–
phenotype evaluation of nail find-
ings in PC. Similarly, Amy Paller 
(Northwestern University, Chicago, IL) 
used IPCRR data to document the nat-
ural history of the disease. Eli Sprecher 
(Tel Aviv Sourasky Medical Center, 
Israel) presented novel data using 
ultrasound that showed subepidermal 
blister formation under PC callosities. 
This may help to explain the exqui-
site pain experienced by PC patients 
as well as the relief they experience 
when the blisters are drained.
Sancy Leachman (University of 
Utah, Salt Lake City) led a discussion 
following the clinical and translational 
sessions to strategize how to prioritize 
future clinical studies and to obtain 
clinical investigator support for these 
endeavors. An ongoing clinical trial 
with lovastatin presented by Irwin 
McLean (University of Dundee), on 
behalf of Peter Hull (University of 
Saskatoon, Canada), built on the dis-
covery from a chemical library screen 
that statins appear to downregulate 
K6a expression (Zhao et al., 2011, this 
issue). In addition, a recently com-
pleted study using systemic rapamycin 
to treat PC was discussed, particularly 
the fact that it might be amenable to 
topical approaches (Hickerson et al., 
2009). The possibility of using epi-
dermal growth factor receptor agents 
was also discussed (Robert Swerlick, 
Emory University, Atlanta, GA). A 
large number of candidate therapies 
were the subject of discussion, but a 
major obstacle to the performance of 
well-designed trials to establish effi-
cacy is the scarcity of clinical inves-
tigators with an interest in taking the 
lead. Approaches to the development 
of working groups were discussed, 
and a clinical working group will be 
created and advertised to interested 
investigators.
progress in delivery of nucleic acids  
to skin
An increasing body of evidence sug-
gests that small interfering RNAs 
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(siRNAs) can potently target and 
selectively inhibit target gene expres-
sion, including genes that cause 
PC. Remarkably, these siRNAs can 
exhibit single nucleotide specificity, 
selectively targeting mutant mRNAs 
with little or no effect on wild-type 
mRNA (Hickerson et al., 2011a, this 
issue). Although a successful clini-
cal trial has been performed using 
TD101 (an siRNA that targets the 
K6a p.Asn171Lys mutation) to treat 
PC, translation of siRNA-based thera-
pies to the clinic has been hampered 
by delivery concerns, including the 
intense pain associated with injec-
tion of large volumes of TD101 into 
PC lesions. Irwin McLean and Roger 
Kaspar reported on major grants that 
have been awarded in the past year 
to facilitate development of “patient-
friendly” nucleic acid delivery sys-
tems (UK Medical Research Council 
and the US National Institutes of 
Health Grand Opportunity, aka “GO 
Delivery!”).
Efforts to identify more patient-
friendly delivery technologies are 
beginning to bear fruit. Emilio 
Gonzalez (Stanford University, 
Palo Alto, CA) and Tycho Speaker 
(TransDerm, Inc., Santa Cruz, CA) 
reported the ability of dissolvable 
microneedle arrays carrying self-
delivery Accell siRNA cargo (but not 
a non-self-delivery control) to inhibit 
preexisting reporter gene expression 
in a green fluorescent protein (GFP) 
transgenic mouse model, using a 
variety of readouts, including intra-
vital imaging and QRT-PCR. Hyejun 
Ra (Stanford University) and Emilio 
Gonzalez reported a dual-axis confo-
cal (DAC) fluorescence imaging sys-
tem that can intravitally monitor the 
effectiveness of siRNA treatment in a 
transgenic GFP mouse model (Ra et 
al., 2011, this issue). Robyn Hickerson 
(TransDerm) reported the ability of 
similar Accell siRNAs to selectively 
inhibit gene expression in human 
epidermal skin equivalents, suggest-
ing that if self-delivery siRNAs can be 
delivered across the stratum corneum 
barrier, they can functionally inhibit 
target gene expression (Hickerson et 
al., 2011b, this issue). In addition, 
an Accell version of TD101 siRNA 
was demonstrated to selectively tar-
get mutant K6a expression in human 
skin equivalents prepared from PC 
patient keratinocytes, with minimal 
effect on wild-type levels, suggest-
ing this technology may perform bet-
ter than the original TD101 siRNA 
in future clinical trials. Fernando 
Larcher (CIEMAT, Madrid, Spain) fur-
ther showed that PC skin equivalents, 
using cells derived from a PC patient 
sole biopsy, retain many PC character-
istics without the need for induction, 
suggesting that this in vivo model will 
be useful for assessing potential PC 
treatments (García et al., 2011, this 
issue).
In the “Moving Forward on Nucleic 
Acid Delivery” session, Leonard 
Milstone led a discussion that reiter-
ated the progress that has been made 
on delivery and emphasized the need 
for additional improvements. Grants 
focusing on nucleic acid delivery 
(Medical Research Council and 
National Institutes of Health, above) 
should facilitate breakthroughs in 
this area. Efficient, patient-friendly 
skin delivery is perhaps the greatest 
remaining hurdle in the translation of 
these potentially transformative tech-
nologies into the clinic.
the path forward
The relatively large number of poten-
tial treatments for pachyonychia con-
genita, including siRNA, iPS cells, 
gene correction, and small-mole-
cule inhibitors such as retinoids and 
statins, provide hope for patients 
with this disorder. However, many 
challenges remain, including (i) an 
incomplete understanding of PC, par-
ticularly with respect to the underly-
ing cause of plantar pain; (ii) the rela-
tively small numbers of PC patients 
(and even smaller numbers of those 
who contain the same mutation), 
which make clinical trials and statis-
tically validating the results difficult; 
(iii) the natural barrier functions of 
the skin, which make delivery of the 
various lead therapeutics to the prop-
er skin compartment a nontrivial hur-
dle; and (iv) continued funding of the 
various ongoing projects. Fortunately, 
there are considerable assets from 
which to draw, including (i) a highly 
motivated and talented group of 
physicians and scientists working 
together (the IPCC) to develop PC 
therapeutics; (ii) the unwavering sup-
port of the Pachyonychia Congenita 
Project and the patients it represents; 
and (iii) the generous support of PC 
research from funding agencies, 
including the National Institutes of 
Health in the United States and the 
Medical Research Council in the 
United Kingdom. The next few years 
should thus be an exciting time for 
rapid growth in the understanding 
of PC and for development of novel 
treatment approaches with the poten-
tial to help not only those with PC but 
also individuals with related skin dis-
orders.
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